Bristol Myers’ Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the…
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
It doesn’t matter your age or experience: taking full advantage of the stock market and investing with confidence…
Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)
Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a…